

[The decisions of the Formulary Group meeting \(Tuesday 17 June 2025\) will be published by 03 July 2025.](#)

### Publication schedule

This information is updated monthly.

### Formulary Group work programme

The Group meets monthly on the third Tuesday of each month (excluding July and December). The following list includes medicines that will be scheduled for review in the next three to four months. It is indicative and may be subject to change.

Medicine and indication	Meeting date
<b>Airomir® 100micrograms/dose inhaler</b>	
<b>Discontinued/withdrawn</b>	
Indication: in adults, adolescents and children aged 4 to 11 years in the management of bronchial asthma, for the relief of wheezing and shortness of breath used on an as required basis. Airomir Inhaler may be used as necessary to relieve attacks of acute dyspnoea and may be used prophylactically before exertion or to prevent exercise-induced asthma. Airomir® Inhaler may also be used in the treatment of the reversible component of airways obstruction.	Jun 2025
<b>cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabozantinib Ipsen)</b>	
<b>SMC 2754</b>	
Indication: as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	TBC
<b>cemiplimab 350mg concentrate for solution for infusion (Libtayo®)</b>	
<b>SMC 2719</b>	
Indication: as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	Aug 2025
<b>dapagliflozin 10mg film-coated tablets (Forxiga®)</b>	
<b>SMC 2763</b>	
Indication: in adults for the treatment of chronic kidney disease (CKD). <b>SMC restriction:</b> in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment:	
- an estimated glomerular filtration rate (eGFR) of 20mL/min/1.73m <sup>2</sup> up to 45mL/min/1.73m <sup>2</sup> , or	
- an eGFR of 45mL/min/1.73m <sup>2</sup> up to 90mL/min/1.73m <sup>2</sup> and either:	
o A urine albumin-to-creatinine ratio (uACR) of 22.6mg/mmol or more, or	
o Type 2 Diabetes Mellitus (T2DM).	Jun 2025

Medicine and indication	Meeting date
<b>elafibranor 80mg film-coated tablets (Iqirvo®)</b> <b>SMC 2714</b>	
Indication: for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.	Aug 2025
<b>empagliflozin 10mg film-coated tablet (Jardiance®)</b> <b>SMC 2642</b>	
Indication: in adults for the treatment of chronic kidney disease. <b>SMC restriction:</b> in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment: - an estimated glomerular filtration rate (eGFR) of 20mL/min/1.73m <sup>2</sup> up to 45 mL/min/1.73m <sup>2</sup> , or - an eGFR of 45mL/min/1.73m <sup>2</sup> up to 90mL/min/1.73m <sup>2</sup> and either: o A urine albumin-to-creatinine ratio (uACR) of 22.6mg/mmol or more, or o Type 2 Diabetes Mellitus (T2DM).	Jun 2025
<b>etrasimod 2mg film-coated tablets (Velsipity®)</b> <b>SMC 2655</b>	
Indication: for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	TBC
<b>ivosidenib 250mg film-coated tablet (Tibsovo®)</b> <b>SMC 2664</b>	
Indication: as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Aug 2025
<b>olaparib 100mg, 150mg film-coated tablets (Lynparza®)</b> <b>SMC 2617</b>	
Indication: in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	TBC
<b>Osvaren® 435mg/235mg film-coated tablets (calcium acetate/magnesium carbonate heavy)</b> <b>Discontinued/withdrawn</b>	
Indication: treatment of hyperphosphatemia associated with chronic renal insufficiency in adults undergoing dialysis (haemodialysis, peritoneal dialysis).	Jun 2025

Medicine and indication	Meeting date
<b>relugolix 120mg film-coated tablets (Orgovyx®)</b>	
<b>SMC 2678</b>	
Indications:	
- for the treatment of adult patients with advanced hormone-sensitive prostate cancer	
- for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy	Jun 2025
- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.	
<b>risankizumab 180mg, 360mg solution for injection in cartridge, 600mg concentrate for solution for infusion (Skyrizi®)</b>	
<b>SMC 2686</b>	
Indication: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.	Jun 2025
<b>ruxolitinib 5mg, 10mg tablets (Jakavi®)</b>	
<b>SMC 2750</b>	
Indication: for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.	TBC
<b>Sandimmun® 25mg, 50mg, 100mg capsules, 100mg/mL oral solution (ciclosporin)</b>	
<b>Discontinued/withdrawn</b>	
Indications: as licensed.	Jun 2025
<b>somapacitan 5mg/1.5mL, 10mg/1.5mL 15mg/1.5mL solution for injection in pre-filled pen (Sogroya®)</b>	
<b>SMC 2629</b>	
Indication: for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).	Jun 2025
<b>SMC restriction:</b> for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).	
<b>talazoparib 0.1mg, 0.25mg, 1mg hard capsules (Talzenna®)</b>	
<b>SMC 2753</b>	
Indication: in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	TBC

Medicine and indication	Meeting date
<b>ublituximab 150mg concentrate for solution for infusion (Briumvi®)</b> <b>SMC 2731</b>	
Indication: treatment of adult with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. <b>SMC restriction:</b> treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Jun 2025
<b>vamorolone 40mg/mL oral suspension (Agamree®)</b> <b>SMC 2721</b>	
Indication: treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.	Jun 2025

END